Caspofungin-non-susceptible Candida isolates in cancer patients

Objectives To identify the frequency of caspofungin-non-susceptible Candida isolates in cancer patients with candidiasis. Methods We reviewed the in vitro susceptibilities (M27-A3 CLSI method) of 650 Candida spp. associated with invasive candidiasis episodes in 582 hospitalized cancer patients (2005...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2010-02, Vol.65 (2), p.293-295
Main Authors: Kofteridis, Diamantis P., Lewis, Russell E., Kontoyiannis, Dimitrios P.
Format: Article
Language:English
Subjects:
Adolescent
Aged
Aged, 80 and over
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antifungal Agents - pharmacology
Biological and medical sciences
Cancer
Candida albicans
Candida albicans - drug effects
Candida albicans - isolation & purification
Candida glabrata
Candida glabrata - drug effects
Candida glabrata - isolation & purification
Candida tropicalis
Candida tropicalis - drug effects
Candida tropicalis - isolation & purification
Candidiasis - microbiology
Drug resistance
Drug Resistance, Fungal
echinocandin resistance
Echinocandins - pharmacology
Female
haematological malignancy
Humans
invasive candidiasis
Lipopeptides
Male
Medical sciences
Middle Aged
Neoplasms - complications
Pharmacology. Drug treatments
Prescription drugs
Yeast
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To identify the frequency of caspofungin-non-susceptible Candida isolates in cancer patients with candidiasis. Methods We reviewed the in vitro susceptibilities (M27-A3 CLSI method) of 650 Candida spp. associated with invasive candidiasis episodes in 582 hospitalized cancer patients (2005–08). Results and conclusions We identified seven caspofungin-non-susceptible Candida strains (three Candida tropicalis, two Candida glabrata and two Candida albicans) from 650 Candida isolates (1%). C. tropicalis (three out of seven) was the most common non-susceptible species isolated. All patients responded to a change of antifungal therapy. Further surveillance should focus on the potential broader emergence of echinocandin resistance, as the clinical use of this antifungal class continues to expand in cancer patients.
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkp444